Clinical Trial Update: A Study to Compare the Glycemic Effects, Safety, and Tolerability of Exenatide Once Weekly to Those of Sitagliptin and Pioglitazone,in Subjects With Type 2 Diabetes Treated With Metformin (DURATION - 2) [Phase 3]

View source ↗

Summary

Phase 3 study comparing once-weekly exenatide with sitagliptin and pioglitazone in patients with type 2 diabetes mellitus on metformin to evaluate glycemic effe…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Type 2 Diabetes Mellitus

Drugs mentioned

• Actos (Pioglitazone)
• BYETTA (Exenatide)
• Januvia (sitagliptin)

Snippet

Sponsor: AstraZeneca | Conditions: Type 2 Diabetes Mellitus | Phase 3 | Status: COMPLETED | Results posted: 2012-06-19